AbbVie to Build New Biologics Manufacturing Site in Singapore
Last week, AbbVie broke ground on a new Singapore manufacturing facility located in Singapore's Tuas Biomedical Park. The company will invest $223 million in the site which will add 24,000 l of biologics drug-substance capacity to AbbVie's global manufacturing network and support current products as well as emerging immunology and oncology compounds within its pipeline.
Construction on the new site is scheduled to begin later this year, with operations expected to start in 2026.
Azita Saleki-Gerhardt, AbbVie executive vice president and chief operations officer, commented: "This expansion announcement represents one of AbbVie's many investments in its Singapore-based operations and the proud continuation of our decade-long partnership with the Government of Singapore."
With this expansion, AbbVie said it has invested more than $740 million in acquiring, modernizing and expanding its Singapore facility over the past ten years. When fully operational, the expanded Singapore manufacturing facility – AbbVie's only manufacturing site in Asia – will employ more than 500 people.
AbbVie and Singapore Economic Development Board officials participate in a groundbreaking ceremony on Jan. 25 for AbbVie’s $223 million expansion of its Singapore manufacturing site. © AbbVie
